(Q28260488)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

P Bentham

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

R Gray

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

E Sellwood

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

P Crome

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

J Raftery

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

AD2000 Collaborative Group

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

English

0 references

publication date

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

41-49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

An estimate of the total worldwide societal costs of dementia in 2005

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Memantine for dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Subcortical vascular dementia: survey of treatment patterns and research considerations.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Anti-inflammatory drugs protect against Alzheimer disease at low doses.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Aspirin, anti-inflammatory drugs and risk of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Risk of Alzheimer's disease and duration of NSAID use.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged > or =80 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

In vitro fibrillogenesis of the amyloid beta 1-42 peptide: cholesterol potentiation and aspirin inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Acetylsalicylic acid decreases tau phosphorylation at serine 422

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Alzheimer disease and cerebrovascular pathology: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Cardiovascular factors in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

15-year longitudinal study of blood pressure and dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Atrial fibrillation and dementia in a population-based study. The Rotterdam Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Diabetes mellitus and the risk of dementia: The Rotterdam Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia: case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Does aspirin affect outcome in vascular dementia? A retrospective case-notes analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Aspirin for vascular dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

1 reference

7 January 2021

Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

The sensitivity to change over time of the Bristol Activities of Daily Living Scale in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Low dose aspirin and cognitive function in the women's health study cognitive cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Clinical trials. Nail-biting time for trials of COX-2 drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Prevalence and severity of microbleeds in a memory clinic setting.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Prevalence and effects of lobar microhemorrhages in early-stage dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970293-4

7 January 2021

10.1016/S1474-4422(07)70293-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18068522%20AND%20SRC:MED&resulttype=core&format=json

release_wqbebbrojfgs5oyuc4uhrypmmq

29 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wqbebbrojfgs5oyuc4uhrypmmq

24 November 2022

mapped directly with Wikidata item

1 reference